Patients with Major Depressive disorder (MDD) have been shown to achieve remission within three months following treatment with SPL026 combined with supportive therapy in Small Pharma’s...
Beckley Psytech has initiated a Phase IIa study of its 5-MeO-DMT candidate – BPL-003 – for Alcohol Use Disorder (AUD), which will take place at King’s...
While psychedelic research has, to date, largely focused on mathematical modelling and resting-state neuroimaging, cognitive neuroscientists are bringing new rigour to the field through the use...
Researchers from the Universidade de São Paulo (USP) and ICEERS have found that ayahuasca may modulate neural networks, and suggest that more research is needed to...
Mind Medicine Australia has provided funding for two studies that will be investigating the use of psilocybin and MDMA.
Detailed brain imaging data from 20 healthy volunteers has revealed how DMT increased connectivity across the brain, with more communication between different areas and systems.
Doug Drysdale, CEO of Cybin Inc.,
In what marks a significant finding in the advancement of psychedelic research, a new study has demonstrated that the location of serotonin 2A receptors (5-HT2A) is...
Tadeusz Hawrot, Founder and Executive Director of the Psychedelic Access and Research European Alliance (PAREA), speaks to Psychedelic Health about how the organisation plans to campaign...
COMPASS Pathways is recruiting participants for its trial investigating the safety and tolerability of its psilocybin formula – COMP360 – for post-traumatic stress disorder (PTSD).